PEOPLE - Lexington makes appointment:
This article was originally published in Clinica
Lexington, Massachusetts-based molecular diagnostics company Predictive Biosciences has named Peter Klemm its first president and CEO. Dr Klemm was formerly CEO of molecular diagnostics company GeneOhm Sciences, which he built from its inception in 2002 and successfully sold to Becton Dickinson in 2006 for $230m. Prior to that, he was CEO of Jomed, a Swiss company that develops and manufactures products for interventional cardiology, radiology and minimally-invasive vascular surgery.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.